Company Description
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited.
Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
| Country | France |
| Founded | 1999 |
| IPO Date | Oct 17, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 181 |
| CEO | Jonathan Dickinson |
Contact Details
Address: 117, Avenue de Luminy, BP 30191 Marseille, 13009 France | |
| Phone | 33 4 30 30 30 30 |
| Website | innate-pharma.com |
Stock Details
| Ticker Symbol | IPHA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $5.50 |
| CIK Code | 0001598599 |
| CUSIP Number | 45781K204 |
| ISIN Number | US45781K2042 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jonathan E. Dickinson B.Sc., M.B.A. | Chief Executive Officer |
| Yannis Morel Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. Sonia Quaratino M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Dr. François Romagné Ph.D. | Founder |
| Eric Vivier D.V.M., M.B.A., Ph.D. | Founder, Senior Vice President and Chief Scientific Officer |
| Dr. Marc Bonneville Ph.D. | Founder |
| Jean Jacques Fournié Ph.D. | Founder |
| Alessandro Moretta M.D., Ph.D. | Founder |
| Frederic Lombard M.B.A. | Senior Vice President and Chief Financial Officer |
| Henry Wheeler M.Sc. | Vice President of Investor Relations and Communication |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2025 | 6-K | Report of foreign issuer |
| Jun 13, 2025 | 6-K | Report of foreign issuer |
| May 30, 2025 | 144 | Filing |
| May 27, 2025 | 6-K | Report of foreign issuer |
| May 23, 2025 | 6-K | Report of foreign issuer |
| May 23, 2025 | 6-K | Report of foreign issuer |
| May 19, 2025 | 6-K | Report of foreign issuer |
| May 15, 2025 | 6-K | Report of foreign issuer |
| May 13, 2025 | 6-K | Report of foreign issuer |
| May 12, 2025 | 6-K | Report of foreign issuer |